Lexicon Pharmaceuticals (NASDAQ:LXRX) Director Raymond Debbane Acquires 100,000 Shares

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Director Raymond Debbane purchased 100,000 shares of Lexicon Pharmaceuticals stock in a transaction on Monday, February 23rd. The shares were acquired at an average cost of $1.47 per share, with a total value of $147,000.00. Following the completion of the transaction, the director directly owned 1,904,186 shares in the company, valued at $2,799,153.42. The trade was a 5.54% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Raymond Debbane also recently made the following trade(s):

• On Friday, February 20th, Raymond Debbane acquired 100,000 shares of Lexicon Pharmaceuticals stock. The shares were acquired at an average price of $1.48 per share, with a total value of $148,000.00.
• On Thursday, February 19th, Raymond Debbane acquired 50,000 shares of Lexicon Pharmaceuticals stock. The stock was acquired at an average price of $1.44 per share, for a total transaction of $72,000.00.

Lexicon Pharmaceuticals Trading Up 3.7%

Shares of Lexicon Pharmaceuticals stock opened at $1.54 on Wednesday. The stock has a market cap of $557.93 million, a PE ratio of -8.08 and a beta of 0.98. The firm has a fifty day moving average price of $1.30 and a 200 day moving average price of $1.31. Lexicon Pharmaceuticals, Inc. has a 1 year low of $0.28 and a 1 year high of $1.83. The company has a debt-to-equity ratio of 0.47, a current ratio of 5.64 and a quick ratio of 5.63.

Analyst Ratings Changes

LXRX has been the topic of several analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a report on Thursday, January 22nd. Wall Street Zen lowered shares of Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, November 15th. Three equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $3.23.

Institutional Investors Weigh In On Lexicon Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in LXRX. Security National Bank of Sioux City Iowa IA purchased a new position in shares of Lexicon Pharmaceuticals during the 4th quarter worth $31,000. Hudson Bay Capital Management LP purchased a new position in Lexicon Pharmaceuticals during the second quarter worth about $26,000. Leonteq Securities AG acquired a new position in Lexicon Pharmaceuticals in the 4th quarter valued at about $34,000. Vermillion & White Wealth Management Group LLC grew its stake in shares of Lexicon Pharmaceuticals by 400.0% in the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 32,500 shares of the biopharmaceutical company’s stock valued at $44,000 after buying an additional 26,000 shares during the period. Finally, EntryPoint Capital LLC acquired a new stake in shares of Lexicon Pharmaceuticals during the 4th quarter worth approximately $39,000. Institutional investors and hedge funds own 74.70% of the company’s stock.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.

The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.